Celon Pharma S.A. (WSE:CLN)

Celon Pharma Balance Sheet

Financials in millions PLN. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	8.35	19.31	26.85	32.36	82.9	147.8
Short-Term Investments	0.75	0.6	48.24	82.18	81.72	79.76
Cash & Short-Term Investments	9.09	19.91	75.09	114.54	164.62	227.55
Cash Growth	-82.69%	-73.49%	-34.45%	-30.42%	-27.65%	417.42%
Accounts Receivable	52.63	41.23	39.26	32.79	27.11	24.67
Other Receivables	14.82	10.94	12.72	15.45	6.59	2.57
Receivables	67.45	52.17	51.99	48.24	33.7	27.25
Inventory	25.17	26.11	30.17	26.41	38.39	23.38
Other Current Assets	3.73	4.08	3.18	0.56	0.87	0.53
Total Current Assets	105.44	102.26	160.43	189.75	237.58	278.7
Property, Plant & Equipment	336.17	303.76	311.66	333.8	341.59	316.57
Long-Term Investments	175.26	6.13	32.69	11.26	13.25	38.12
Other Intangible Assets	21.33	15.69	8.15	14.29	21.15	27.81
Long-Term Deferred Tax Assets	2.22	-	21.55	19.05	28.14	31.94
Long-Term Deferred Charges	-	-	-	0.68	0.68	1.36
Other Long-Term Assets	30.31	18.84	0.22	0.47	0.38	12.64
Total Assets	670.73	457.46	543.8	569.31	642.76	707.14

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	40.99	17.07	15.43	10.51	17.47	11.87
Accrued Expenses	9.88	12.45	8.1	7.39	6.8	3.11
Short-Term Debt	13.25	-	1.53	12.75	-	-
Current Portion of Long-Term Debt	-	1.61	-	-	-	-
Current Portion of Leases	7.57	7.16	7.14	7.13	19.43	6.56
Current Unearned Revenue	6.58	11.83	17.92	31.09	56.42	55.83
Other Current Liabilities	9.33	13.15	16.78	17.48	16.32	8.99
Total Current Liabilities	87.6	63.27	66.9	86.34	116.44	86.36
Long-Term Debt	0.53	1.43	-	-	-	-
Long-Term Leases	32.32	8.74	8.26	5.71	7.39	8.35
Long-Term Unearned Revenue	20.28	19.75	20.22	22.88	25.62	29.85
Long-Term Deferred Tax Liabilities	0.23	-	2.85	3.01	1.32	6.04
Other Long-Term Liabilities	0.98	1.03	0.36	5.81	12.35	22.53
Total Liabilities	141.95	94.21	98.59	123.75	163.12	153.14

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	5.39	5.39	5.39	5.11	5.1	5.1
Additional Paid-In Capital	516.81	516.81	551.25	543.23	587.1	613.51
Retained Earnings	2.59	-159.91	-114.96	-108.64	-119.79	-91.67
Comprehensive Income & Other	4.01	0.96	3.53	5.85	7.23	27.07
Shareholders' Equity	528.78	363.25	445.21	445.56	479.65	554
Total Liabilities & Equity	670.73	457.46	543.8	569.31	642.76	707.14

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	53.68	18.94	16.93	25.59	26.82	14.92
Net Cash (Debt)	-44.58	0.97	58.16	88.95	137.8	212.63
Net Cash Growth	-	-98.34%	-34.62%	-35.45%	-35.19%	1049.56%
Net Cash Per Share	-0.84	0.02	1.08	1.74	2.70	4.55
Filing Date Shares Outstanding	53.86	53.86	53.86	51.06	51.04	51
Total Common Shares Outstanding	53.86	53.86	53.86	51.06	51.04	51
Working Capital	17.85	38.99	93.53	103.41	121.14	192.34
Book Value Per Share	9.82	6.74	8.27	8.73	9.40	10.86
Tangible Book Value	507.46	347.56	437.06	431.26	458.5	526.19
Tangible Book Value Per Share	9.42	6.45	8.12	8.45	8.98	10.32
Land	6.35	-	6.35	6.35	6.35	6.35
Buildings	157.97	-	157.97	146.4	146.35	146.08
Machinery	377.86	-	235.52	272.86	190.43	177.34
Construction In Progress	45.75	-	15.75	79.95	74.3	50.63

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Sep 3, 2026

Data Sources Report a data error